首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1378763

多发性硬化症治疗市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年11月02日 | 出版商:

IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

抽象的

2022年，全球多发性硬化症治疗市场规模达到258亿美元。展望未来， IMARC Group预计到2028年市场规模将达到336亿美元，2022-2028年复合年增长率（CAGR）为4.5%。

多发性硬化症 (MS) 是一种慢性发炎性免疫介导疾病，可导致脊髓和大脑神经细胞脱髓鞘、轴突横断和神经退化。一些常用的疗法包括注射、口服和输注药物、肌肉鬆弛剂、抗忧郁药物和物理疗法。注射药物，如干扰素-β和醋酸格拉默，可在皮下或肌肉内注射；口服药物包括富马酸二甲酯、特立氟胺和克拉屈滨；输注治疗包括 Ocrelizumab、Natalizumab 和 Alemtuzumab，均以静脉注射。这些药物有助于控制症状，最大限度地减少復发频率并控制患者的心率和血压。

全球復发缓解型多发性硬化症(RRMS)、原发性进展型多发性硬化症(PPMS)、继发性进展型多发性硬化症(SPMS) 和进行性復发型多发性硬化症(PRMS) 的盛行率不断增加，是推动多发性硬化症成长的关键因素之一。市场。此外，老年人口的增加更容易患此类疾病，这也推动了市场的成长。医疗保健提供者广泛使用免疫抑制剂来控制自体免疫攻击并防止多发性硬化症患者復发。此外，各种技术进步，例如用于有效治疗多发性硬化症的创新单株、免疫调节剂、免疫抑制剂和干扰素的开发，也是其他主要的生长诱导因素。除此之外，已开发国家和新兴国家的政府都在发起运动，以提高大众对可用治疗替代方案的认识，这反过来又为市场创造了积极的前景。其他因素，包括广泛的研发（R&D）活动以及医疗保健基础设施的改善，预计将进一步推动市场发展。

本报告回答的关键问题：

迄今为止，全球多发性硬化症治疗市场表现如何，未来几年将如何表现？
COVID-19 对全球多发性硬化症治疗市场有何影响？
主要区域市场有哪些？
基于药物的市场区隔是什么？
根据药物类型分類的市场是怎么样的？
根据给药途径，市场的分化为何？
基于配销通路的市场区隔是什么？
产业价值链的各个阶段是什么？
该行业的关键驱动因素和挑战是什么？
全球多发性硬化症治疗市场的结构是什么？谁是主要参与者？
产业竞争程度如何？

免疫调节剂
- 市场走向
- 主要类型
  - 科帕松
  - Avonex/Plegridy
  - 吉尔内亚
  - 蒂萨布里
  - 倍他龙/Extavia
  - 特西菲德拉
  - 雷比夫
  - 安皮拉
- 市场预测
免疫抑制剂
- 市场走向
- 主要类型
  - 奥巴焦
  - 莱姆特拉达
  - 奥瑞珠单抗
  - 津布里塔
- 市场预测

第 7 章：按药物类型分類的市场细分

生物药
- 市场走向
- 市场预测
小分子药物
- 市场走向
- 市场预测

第 8 章：按管理途径分類的市场

口服
- 市场走向
- 市场预测
可注射
- 市场走向
- 市场预测
静脉
- 市场走向
- 市场预测

第 9 章：按配销通路分類的市场区隔

医院药房
- 市场走向
- 市场预测
零售药局
- 市场走向
- 市场预测
网路药局
- 市场走向
- 市场预测

第 10 章：按地区分類的市场细分

北美洲
- 美国
  - 市场走向
  - 市场预测
- 加拿大
  - 市场走向
  - 市场预测
亚太地区
- 中国
  - 市场走向
  - 市场预测
- 日本
  - 市场走向
  - 市场预测
- 印度
  - 市场走向
  - 市场预测
- 韩国
  - 市场走向
  - 市场预测
- 澳洲
  - 市场走向
  - 市场预测
- 印尼
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
欧洲
- 德国
  - 市场走向
  - 市场预测
- 法国
  - 市场走向
  - 市场预测
- 英国
  - 市场走向
  - 市场预测
- 义大利
  - 市场走向
  - 市场预测
- 西班牙
  - 市场走向
  - 市场预测
- 俄罗斯
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
拉丁美洲
- 巴西
  - 市场走向
  - 市场预测
- 墨西哥
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
中东和非洲
- 市场走向
- 按国家/地区分類的市场细分
- 市场预测

第 11 章：SWOT 分析

概述
优势
弱点
机会
威胁

第 12 章：价值链分析

第 13 章：波特五力分析

概述
买家的议价能力
供应商的议价能力
竞争程度
新进入者的威胁
替代品的威胁

第 14 章：价格分析

第15章：竞争格局

市场结构
关键参与者
关键参与者简介
- Abbvie Inc.
- Bayer Aktiengesellschaft
- Biogen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.

简介目录图表

Product Code: SR112023A2571

Abstract

The global multiple sclerosis therapies market size reached US$ 25.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2022-2028.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.

Breakup by Drug:

Immunomodulators

Copaxone

Avonex/Plegridy

Gilneya

Tysabri

Betaseron/Extavia

Tecifidera

Rebif

Ampyra

Immunosuppressants

Aubagio

Lemtrada

Ocrelizumab

Zinbryta

Breakup by Drug Type:

Biologic Drugs

Small Molecule Drugs

Breakup by Route of Administration:

Oral

Injectable

Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
What are the key regional markets?
What is the breakup of the market based on the drug?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple sclerosis therapies market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug

6.1 Immunomodulators
- 6.1.1 Market Trends
- 6.1.2 Major Types
  - 6.1.2.1 Copaxone
  - 6.1.2.2 Avonex/Plegridy
  - 6.1.2.3 Gilneya
  - 6.1.2.4 Tysabri
  - 6.1.2.5 Betaseron/Extavia
  - 6.1.2.6 Tecifidera
  - 6.1.2.7 Rebif
  - 6.1.2.8 Ampyra
- 6.1.3 Market Forecast
6.2 Immunosuppressants
- 6.2.1 Market Trends
- 6.2.2 Major Types
  - 6.2.2.1 Aubagio
  - 6.2.2.2 Lemtrada
  - 6.2.2.3 Ocrelizumab
  - 6.2.2.4 Zinbryta
- 6.2.3 Market Forecast

7 Market Breakup by Drug Type

7.1 Biologic Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Small Molecule Drugs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Intravenous
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abbvie Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Bayer Aktiengesellschaft
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Biogen Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Bristol-Myers Squibb Company
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 SWOT Analysis
- 15.3.6 GlaxoSmithKline Plc
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Merck & Co. Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Novartis AG
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Sanofi S.A.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Teva Pharmaceutical Industries Ltd.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis

简介目录图表

List of Figures

Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2022
Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2022
Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2022
Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2022
Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million US$), 2023-2028
Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 7: Global: Multiple Sclerosis Therapies Market Structure
Table 8: Global: Multiple Sclerosis Therapies Market: Key Player

02-2729-4219

+886-2-2729-4219